Table 4 Univariate and multivariate logistic regressions for the risk of drug resistance
Explanatory variable | Pan-susceptible n = 189 (89.15%) | Resistant n = 23 (10.85%) | Univariate regression: associations with DR | Multivariate regression: associations with DR | ||
|---|---|---|---|---|---|---|
| Â | Â | Â | Crude OR (95% CI) | p-value | Adj. OR (95% CI) | p-value |
Study site n (%) | Â | Â | Â | Â | Â | Â |
Goroka* | 50 (26.46) | 6 (26.09) | Â | Â | Â | Â |
Alotau | 58 (30.69) | 8 (34.78) | 1.1 (0.4 - 3.5) | 0.808 | Â | Â |
Madang | 81 (42.86) | 9 (39.13) | 0.9 (0.3 - 2.8) | 0.890 | Â | Â |
Sex, n (%) | Â | Â | Â | Â | Â | Â |
Men* | 92 (48.68) | 11 (47.83) | Â | Â | Â | Â |
Women | 97 (51.32) | 12 (52.17) | 1.0 (0.4 - 2.5) | 0.939 | Â | Â |
Age - median years [IQR] | 29 [24-40] | 31 [25-50] | 1.0 [1.0 - 1.1] | 0.267 | Â | Â |
HIV status | Â | Â | Â | Â | Â | Â |
Negative* | 67 (83.75) | 11 (78.57) | Â | Â | Â | Â |
Positive | 13 (16.25) | 3 (21.43) | 1.4 (0.3 - 5.7) | 0.636 | Â | Â |
TB treatment history, n (%) | Â | Â | Â | Â | Â | Â |
No* | 155 (92.26) | 15 (71.43) | Â | Â | Â | Â |
Yes | 13 (7.74) | 6 (28.57) | 5.5 (1.8 - 16.8) | 0.003 | 4.2 (1.1 - 16.7) | 0.040 |
Lineage 2 | Â | Â | Â | Â | Â | Â |
No* | 72 (57.14) | 6 (35.29) | Â | Â | Â | Â |
Yes | 54 (42.86) | 11 (64.71) | 2.44 (0.85 - 7.02) | 0.097 | 3.4 (1.0 - 11.2) | 0.041 |